Category: Blog

09
Mar

Data Shows that Medical Cannabis Sales are set to Rise

NEW YORKMarch 9, 2018 / — According to Hexa Research, the U.S. medical cannabis market size was valued at USD $5.44 Billion in 2016 and is expected to hit USD $19.48 billion by 2024. The industry is expected to witness swift growth during the forecast period due to the numerous medical benefits of cannabis products and the accelerating pace of legalization of such products in the United States. The report also indicated that the increasing demand for medical cannabis is due to the increasing ageing population. In 2016, rising number of patients diagnosed with chronic pain has resulted in increasing use of cannabis. The report estimated that the demand for medical cannabis for arthritis will grow at a CAGR of 17.8% over the projected period as it forecasted more adults and children will have arthritis. Cannabis infused edibles is also expected to grow at a CAGR of 17.8% over the forecast period. Pivot Pharmaceuticals Inc. (OTC: PVOTF), GW Pharmaceuticals plc (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA), General Cannabis Corp. (OTC: CANN).

Related image

California’s new recreational cannabis laws went into effect on January 1st, 2018. While California is the largest market, Canada is projected to show strong sales as well. Deloitte’s report estimates the Canadian market will be worth at least $5B in sales in 2018. Tom Adams, Editor-in-Chief at Arcview Market Research and Principal Analyst at BDS Analytics explained, “Our data shows positive indicators across the board for the legal cannabis industry, in North America and around the globe. The passage of the 2016 ballot initiatives and continued maturation of the existing Adult-Use markets are the primary drivers of the growth this year. That’s nothing compared to what we can expect in 2018 and beyond from Nevada’s tourism, and California and Canada planning to launch Adult-Use sales in 2018.”

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) also listed on the Canadian Stock Exchange under the Ticker ‘PVOT’. Earlier this week the company announced, “The acquisition of Thrudermic, LLC (“TDL” or “Thrudermic”), a privately held North Carolina company. Pivot previously announced a licensing agreement with Thrudermic but has decided to exercise its option to acquire 100% of TDL. Pivot will pay $1.00 (USD) for all of the issued and outstanding units of Thrudermic, and issue an aggregate of 500,000 common shares in the capital of Pivot to Dr. Joseph Borovsky and Dr. Leonid Lurya for their intellectual property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology. Dr. Borovsky, has been appointed Pivot’s Vice President, Product Formulation, and Dr. Lurya has been appointed Executive Director, Product Formulation.”

The TDL Transdermal Nanotechnology is intended for the formulation and delivery of dosable bio-cannabis products. On behalf of Pivot, Thrudermic recently filed three additional patent applications related to improved formulation and delivery for new routes of administration of cannabinoids and will increase the number of products in the Company’s pipeline.

“Thrudermic is very excited to become part of the Pivot organization. Our lipid-based nano-dispersion technology is well suited for the emerging cannabis industry. Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” states Dr. Borovsky.

Dr. Borovsky, formerly the director of research and development for Mead Corporation, received his Bachelor of Science degree in Chemistry from UCLA and his Ph.D. in Physical Organic Chemistry from the University of Massachusetts at Amherst. He also completed a year of post-doctoral research in Medicinal Chemistry at Washington State UniversityCollege of Pharmacy and was a Research Fellow in Synthetic Organic Chemistry at Harvard University. Dr. Lurya is the inventor of Thrudermic transdermal technology and has authored several patents. He received his MD from the Moscow Medical Institute No. 2, Russia, and then completed his PhD in Biophysics, Chemical Physics Department at the Weizmann Institute of Science, Israel.”

Dr. Patrick Frankham, Pivot’s CEO, comments, “Thrudermic is Pivot’s fourth disruptive formulation and delivery platform for cannabinoids. We are thrilled that Dr. Borovsky and Dr. Lurya have agreed to join us to develop and commercialize therapeutic bio-cannabis products. They are highly experienced formulations experts with many years of pharmaceutical industry know-how. Pivot continues to position itself as a leader in the delivery of dosable bio-cannabis, something that consumers and regulatory agencies will demand as legalization occurs.”

GW Pharmaceuticals plc (NASDAQ: GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. On February 27, 2018, the company announced the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). GW is currently recruiting a Phase 3 clinical trial of Epidiolex® (cannabidiol) as an adjunctive therapy for the treatment of seizures associated with TS, with data expected in the second half of 2018. Subject to positive results, GW expects to submit regulatory applications in 2019 for Epidiolex in TS in both the U.S. and Europe.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric diseases with high unmet medical needs. Recently, the company announced the results of a positive meeting held with the U.S. Food and Drug Administration (FDA) regarding its planned development strategy for ZYN002 in Fragile X syndrome (FXS). FXS is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability and autism spectrum disorder. ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a patent-protected permeation-enhanced transdermal gel. Zynerba has received U.S. Orphan Drug designation for the use of CBD as a treatment of FXS. Currently, there are no approved therapies to treat FXS or its most common symptoms. Based on the company’s dialogue with the FDA, the Company expects to initiate a single pivotal study mid-year 2018 to support a New Drug Application (NDA) for ZYN002 in FXS. The FDA and the Company are in agreement that the primary and key secondary endpoints for the study should assess observable behaviors in patients with FXS as reported by the caregiver using the validated Aberrant Behavior Checklist in Fragile X syndrome (ABC-FXS).

Cara Therapeutics, Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Cara’s most advanced CB compound, CR701, is in preclinical development. Dr. Joseph Stauffer, CMO Cara Therapeutics, said, “Cannabinoid Receptor Agonists like CR701 have the potential to provide improved pain relief for patients suffering from neuropathic pain.”

General Cannabis Corp. (OTCQB: CANN) is the comprehensive national resource for the highest-quality service providers available to the regulated cannabis industry. On February 2, 2018, the company announced that its client, Green Leaf Medical LLC, a leading grower and supplier of medical cannabis in Maryland, has successfully harvested its first crop and has passed all state-required laboratory tests. Now producing an estimated 500-600 pounds of high-quality medical marijuana on a monthly basis, Green Leaf is one of the leading fully approved suppliers in Maryland. Green Leaf also announced that it has begun the next phase of its expansion, increasing the size of its facility to approximately 50,000 square feet, a 67 percent increase from current capacity. The expanded grow house should be completed before the end of the year, raising production totals to nearly 1,000 pounds per month.

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pivot pharmaceuticals inc. financial news dissemination and PR services, FinancialBuzz.com has been compensated five thousand dollars by vintage capital group inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

SOURCE FinancialBuzz.com

12
Jan

2018 Could be a Breakout Year for Cannabis Companies

NEW YORK/ — Entering a new year is exciting, especially when the future holds the promise of expanding marketplaces and business opportunities. From growers and processors to the essential support services and an increasing number of retailers, cannabis companies are looking at 2018 as a breakout year for unprecedented growth. California’s launch of legal marijuana for adult recreational use kicked off January 1, and Canada is set to follow the same path in July 2018. An article in Newsweek reveals at least 12 states are poised to consider legalizing some form of marijuana in 2018 (http://nnw.fm/1ETMq), marking the latest in a quick volley of changes being implemented by lawmakers and the public as more than 60 percent of Americans say they support legalization for adults (http://nnw.fm/pFa4w). Companies nimble enough to take advantage of these promising changes include DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) (DJACF Profile), Growlife, Inc. (OTC: PHOT), United Cannabis Corp. (OTC: CNAB), Cannabis Wheaton Income Corp. (TSX-V: CBW) (OTC: CBWTF) and Supreme Cannabis Company, Inc. (TSX-V: FIRE) (OTC: SPRWF).

Acquisitions, deal-making, and expansion plans are on the minds of many in the cannabis sector as 2018 enters the world. A new Viridian Cannabis Deal Tracker report states the amount of financing raised in 2017 to support the coming cannabis boom is a staggering $2 billion in Canada alone, according to an article in the Financial Post (http://nnw.fm/Lxo1J).

“While the medical market is expected to continue to grow over the next several years, the size of the coming adult-use market is expected to far exceed that of the medical side,” said Harrison Phillips, Vice-president at Viridian, told the Financial Post. “Companies have been raising significant amounts of capital, primarily to increase capacity to satisfy the coming surge in expected demand.”

For DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF), 2017 was full of progress and the development of several successful ventures that will help the company gain a secure foothold in the recreational cannabis market in the new year. DOJA CEO Trent Kitsch in the company’s 3rd Quarter 2017 report (http://nnw.fm/Uv2Dv) praised the company’s team effort to make 2017 a banner year, stating, “I am very proud of our team’s year-to-date accomplishments. We have reached a number of milestones in less time and for less investment than originally budgeted.”

DOJA is a premium cannabis lifestyle brand featuring the highest quality handcrafted strains in Canada. DOJA’s wholly owned subsidiary, Northern Lights Marijuana Company, is a Health Canada licensed cannabis producer located in Kelowna within the heart of British Columbia’s picturesque Okanagan Valley. The company recently harvested and cured its first batches of premium handcrafted cannabis flower, requested a pre-sales license inspection from Health Canada, and began construction of the FUTURE LAB’s 22,580-square-foot state-of-the-art extraction facility and lab that can support greatly increased production capacity – all impressive milestones for a company committed to establishing itself as Canada’s leading lifestyle cannabis brand (http://nnw.fm/qXT1m ).

“We know that iconic brands are backed by iconic products, so our attention has been placed firmly on the art of growing, trimming and curing to ensure the quality and consistency of our handcrafted cannabis flower,” Kitsch said. “Looking to the future there are a number of initiatives that we plan on executing that will further differentiate the DOJA brand and create value for our shareholders.”

Underpinning that statement, DOJA on December 21 revealed its binding letter of intent with Tokyo Smoke to acquire all of its issued and outstanding shares http://nnw.fm/9ON1k). The proposed merger will create a unique cannabis company – to be named Hiku Brands Company Ltd. – that combines a retail-focused cannabis company with DOJA’s specialty cannabis flower production facilities. The company also announced a strategic equity investment of approximately $10 million into the newly-combined company by Aphria Inc. The combination of cannabis production, retail footprint and a portfolio of cannabis brands is expected to provide the newly formed company the opportunity to realize the significant value of complete vertical integration.

In October the company announced its plan to expand its production capacity with the build-out of its new, much larger growing facility.

“The Acquisition is a game changer for DOJA, it allows us to expand our production capacity by almost 8 times, diversity our strain production, integrate a world class extraction lab and leverage the economies of scale that come from a larger growing space,” Kitsch said in a news release (http://nnw.fm/rWR4Q). “Our strategy has always been to reach 5,000 kg of cannabis production per year by the end of 2018, with the addition of FUTURE LAB we project we will reach our goal in less time and for less capital investment than previously budgeted. The FUTURE LAB has 325 feet of highway frontage which will be utilized to promote DOJA’s cannabis lifestyle brand to the 1.9 million-plus visitors to the Okanagan each year and the 40,000 commuters that drive past the facility each day.”

Expanding DOJA’s cultivation capacity and scale provides a near-term supply source for dried cannabis flower that is grown, trimmed and cured in a premium fashion at a price per gram that is within the company’s control – ensuring DOJA remains competitive on a national level. DOJA’s FUTURE LAB state-of the-art extraction lab will drive innovation in the cannabis concentrates and edibles sector, which company officials expect will overtake cannabis whole flower sales in the future.

Closing out 2017, the company recently finalized a previously announced bought deal private placement of convertible debenture units, raising $17.25 million to be used for capital projects and general corporate purposes (http://nnw.fm/WcBi8) as it continues its pattern of growth.

Growing healthy and productive cannabis isn’t done without a great deal of help from Mother Nature and a host of specialty support services. As a nationally recognized cultivation brand for the cannabis industry, Growlife (OTC: PHOT) provides world-class hydroponic equipment, lighting, nutrients, media, and other cultivation supplies to commercial and urban operations. Based in the state of Washington, GrowLife has added an all-in-one home cultivation system called “GrowLife Cube Pro to its product offerings. The company is introducing the product as a way to service the exploding recreational cannabis markets in California and other states where adults will be permitted to cultivate up to six plants per adult under local law (http://nnw.fm/B33cS ).

Denver-based United Cannabis (OTCQB: CNAB) is constructing a state-of-the-art industrial hemp processing plant that will include extraction, purification, testing and processing equipment, as well as packaging, fulfillment and secure storage capabilities, according to a news release (http://nnw.fm/klBB1). The company, which provides consulting services, proprietary products and licenses its intellectual property to businesses in the cannabis industry, is branching out to provide contract manufacturing to farmers working under the 2014 Federal Farm Bill and Colorado’s Department of Agriculture’s Industrial Hemp Program. Farmers in the program will be able to convert harvested industrial hemp plants into a range of products, from simple extracts to capsules to sublingual drops, and have them packaged for resale, the company states in the press release.

Cannabis Wheaton Income (TSX-V: CBW) (OTCQB: CBWTF) is also advancing its footprint in the cannabis sector by entering into a letter of intent with FV Pharma Inc. Under the agreement, Cannabis Wheaton will develop all aspects of FV’s cannabis cultivation facility in mutually agreed staged phases, creating the largest indoor cannabis cultivation and processing facility in the world. A joint press release states (http://nnw.fm/l6wmD). The FV facility, located one hour east of Toronto, Canada, is an existing 620,000 square feet of building space once used by KRAFT® as a food manufacturing facility.

Another Canadian company committed to becoming a leading cultivator and distributor of specialized cannabis is Supreme Cannabis Company (TSX-V: FIRE) (OTC: SPRWF), which recently changed its name from Supreme Pharmaceuticals Inc. The company’s 7ACRES subsidiary is a federally licensed producer of medical cannabis with a 342,000-square-foot hybrid greenhouse facility in Kincardine, Ontario. The recent purchase of six acres adjacent to this facility is expected to produce high-quality “California-Style” cannabis for the premium product segment once construction of an indoor cultivation facility is completed, the company stated in a news release (http://nnw.fm/Y9Ira ).

2018 may certainly turn out to be a rollercoaster for the cannabis industry, with more participants than ever punching a ticket to ride. But there are ample opportunities for growth in various sectors of a global industry that Grand View Research, Inc. expects will reach $55.8 billion by 2025 (http://nnw.fm/LuR6w). Other industries such as marketing, software, packaging, energy, banking, blockchain technology and biotechnology are also taking notice and seeing opportunities in the burgeoning field as marijuana continues its transformation from a hidden, underworld product to a massive economic force.

About NetworkNewsWire 

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Disclaimer: NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

NetworkNewsWire (NNW) is affiliated with the Investor Based Brand Network (IBBN).

About IBBN

Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

 

SOURCE NetworkNewsWire

12
Jan

Cannabis News — Liquid Cannabis Revolutionizing Industry

Wax Liquidizer found an option for liquidizing cannabis that took 10 seconds and was surprisingly easy.

DENVERJan. 11, 2018 / — The Cannabis industry is being revolutionized with liquid cannabis. This new form of Marijuana is allowing cannabis users to vape marijuana. The benefits of using liquid cannabis may explain this phenomenal growth.The use of a liquid cannabis allows users to vape the product and enjoys all of its properties with increased benefits.

  1. Discreet Vaping with little to no smell
  2. Quick and easy use of cannabis with quick results
  3. Fewer tars ingested as compared to smoking

Currently, consumers have two options in obtaining liquidized Marijuana. The first option is to buy pre-filled cannabis vape pen cartridges. The second option is to make your own liquidized cannabis vape oil.

Wax Liquidizer found an option of liquidizing marijuana concentrates that took 10 seconds and left them very surprised at just how easy it is to make liquid cannabis.  Liquidizing weed was surprisingly easy with substantial savings compared to buying the pre-filled cartridges.

The prefilled vape cartridges that come loaded with liquid cannabis hold .5ml and cost on average $35 to $50.  The DIY liquidized cartridges use concentrates that sell from $25 to $30 a gram. One gram of concentrate combined with 2ml of Liquidizer provides the user 3ml of liquid cannabis, that’s 6 times more liquid marijuana for less than one cartridge.

In an online interview with John McKenna, the CEO of Wax Liquidizer stated: “I believe people enjoy the ability to create their own custom combinations of flavors, concentrates and strength of liquid cannabis as much as they do saving money on pre-filled cartridges.”  Wax Liquidizer has been instrumental in providing consumers a method to create their own liquid cannabis and vape cartridges.

The use of liquidized cannabis continues to grow for both pre-filled cannabis products and liquidizer. The pre-filled cartridges do have limitations in shipping due to legalities that the cannabis industry faces. Wax Liquidizer contains no cannabis, thus does not face the same legal ramifications that pre-made liquid cannabis does, and is readily available throughout the United States and now has many global distributors.

To learn more about how to Liquidize cannabis go to https://www.waxliquidizer.com

 

SOURCE Wax Liquidizer

11
Jan

Puration to Launch Flavored EVERx CBD Infused Sports Water at Arnold Schwarzenegger Sports Festival, March 1st, 2018

DALLAS/ — Puration, Inc. (USOTC: PURA) announced the company will officially launch its new Strawberry Kiwi and Lemon Lime flavored EVERx CBD Infused Sports Waters at Arnold Schwarzenegger’s Annual Arnold Sports Festival (formerly the Arnold Classic) in Columbus, OhioMarch 1-4, 2018. Puration is returning to the Arnold for a second consecutive year after introducing EVERx for the first time ever at last year’s Arnold Sports Festival. This year is the 30th Anniversary of the Arnold Sports Festival which is now host to more athletes than the Olympics with over 70 sporting events and 18,000 athletes. The Arnold will include an Expo with over 1,000 booths.

EVERx has become a leading brand name in the CBD infused marketplace and one of the only CBD infused products in the sports nutrition marketplace. In a Forbes Magazine article about the market for CBD products separate from marijuana products, the CBD market is predicted to be a $3 billion market by itself in 2021. EVERx is on shelves now at Drug Emporium and the company expects to announce additional retail locations where EVERx can soon be found.

Canada & California Expansion and New Subsidiary to Unlock Shareholder Value

Puration recently announced plans to launch new cannabis infused beverage lines into Canada’s legal $8 billion marketin addition to announcing plans to open a cannabis extraction facility into California’s legal $10 billionmarket. Puration’s extraction capacity is being structured into a new subsidiary in a first step to unlock shareholder value by delineating between the company’s patented extraction business and cannabis infused beverage business.

 

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

SOURCE Puration, Inc.

11
Jan

Data Projects Increased Demand for the Legalized Cannabis Market

NEW YORK/ — According to a new report published by Arcview Market Research, retail cannabis sales will grow 33 percent to nearly $10 billion in 2017 and the legal cannabis market is expected to reach $24.5 billion by 2021, with a compound annual growth rate of 28 percent. The report indicated that medical cannabis market in California is already as big as the total markets of ColoradoWashington, and Oregon combined. In 2018, cannabis for recreational use has become legal in California, the world’s sixth largest economy. According to BDS Analytics, the cannabis market in California is expected to reach $5.1 billion in 2019. Global Payout, Inc. (OTC: GOHE), Surna Inc. (OTC: SRNA), Easton Pharmaceuticals, Inc. (OTC: EAPH), Cannabis Science, Inc. (OTC: CBIS), CV Sciences, Inc. (OTC: CVSI)

According to another report from Arcview Market Research, consumers in North America spent about $53 billion in the legal and illegal cannabis markets in 2016. “The enormous amount of existing, if illicit, consumer spending sets cannabis apart from most other major consumer-market investment opportunities throughout history,” said Troy Dayton, CEO of Arcview. Unlike most other industries throughout history, “the cannabis industry doesn’t need to create demand for a new product or innovation – it just needs to move demand for an already widely-popular product into legal channels.”

Global Payout, Inc. (OTC: GOHE) earlier today the company just announced that, “its majority owned subsidiary, MoneyTrac Technology, Inc. (“MTRAC” “MoneyTrac”, the “Company”) has executed a Sales and Marketing Management Agreement with High Grade Management Group, Inc. (“HGMG”) to guide the development and implementation of a sales and marketing campaign to support the successful launch of HGMG’s Apple Vapes products.”

Aiming to revolutionize and capture a significant share of the multi-million-dollar vape market space, HGMG has introduced Apple Vapes. This new line of products delivers innovative and high-quality vape pens, chargers, and oils to consumers and retailers in one of the fastest growing market spaces. In addition to providing MTRAC with a direct source of revenue through the retainer they will receive for sales and marketing services, the agreement also serves as reinforcement of MTRAC’s expanding business development service arm which is directed towards the growing number of businesses in the underserved cannabis industry.

Image result for legalized cannabis

MTRAC CEO, Vanessa Luna said: “This agreement is an excellent opportunity for MoneyTrac to play a strategic role in developing effective brand awareness for HGMG’s Apple Vapes product line. The support and expertise that I anticipate our business development team will be able to lend to HGMG will undoubtedly provide them with the invaluable tools and resources necessary to take full advantage of a rapidly expanding marketplace.”

Said HGMG CEO, Mark Glover: “As we look to capitalize on the multi-million-dollar vape industry, securing a partnership like this with MoneyTrac is absolutely vital in making sure we make a significant splash in this competitive market space as well as ensure that Apple Vapes is positioned to become a consistent revenue powerhouse by delivering the most innovative and top quality vape products to consumers and retailers in the industry.”

Surna Inc. (OTCQB: SRNA) develops innovative technologies and products that monitor, control and or address the energy and resource intensive nature of indoor cannabis cultivation. On November 14, 2017, the company announced operating and financial results for the three and nine months ended September 30, 2017. They will not be hosting a conference call following the release of our financial results. Revenue for the three months ended September 30, 2017was $1,566,000 compared to $1,171,000 for the three months ended September 30, 2016, an increase of $395,000, or 34%. Recent and anticipated regulatory changes involving medicinal and/or recreational cannabis use in various jurisdictions, such as California, tends to be a leading indicator for the granting of licenses for new facility construction. As more new cultivation facilities become licensed, the company have an expanded set of opportunities and customers to whom they can potentially sell their systems.

Easton Pharmaceuticals, Inc. (OTC: EAPH) is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. On October 20, 2017, the company announced its final payment which completes its $1.3 Million CDN JV agreement with Canadian based 1124123 Ontario Limited (o/a – Alliance Group) towards a 50% property ownership interest and various businesses including the cultivation of medical / recreational marijuana for national Canadian market. Pursuant to this closed agreement, Easton’s JV partner, Alliance Group (1124123 Ontario Limited) have been advised by its legal representation that it has cleared its last license exemption hurdles which clears a path for Alliance to grow, cultivate and distribute medical / recreational marijuana for the country of Canada. This has now resulted in Alliance Group bringing forward interim facility engineering plans with expectations of a completed greenhouse growing facility within 6 months which would be near the anticipated national launch date of recreational / medical marijuana for the country of Canada. Recreational marijuana has been made legal nationally in Canada and is expected to be launched in late spring of 2018 where many industry observers have estimated a huge shortage of marijuana product once launched.

Cannabis Science, Inc. (OTC: CBIS) takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. On December 28, 2017, the company announced that its expansion plans are progressing rapidly as the final negotiations have been completed for the third medical marijuana dispensary in California. The Company is preparing the final documents now to complete integration of its third medical marijuana operations for the California market opening.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. On November 14, 2017, the company announced it has been named on Deloitte’s Technology Fast 500™, an annual ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy tech sectors in North America. The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016, with CV Sciences growing by 403% during this period.

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

SOURCE FinancialBuzz.com

11
Jan

Control Your Cannabis Grow with New Michigan Automation Company, Growater Controls

Engineers and developers at Growater Controls focus on Michigan’s emerging cannabis industry.

Growater Controls

ROYAL OAK, Mich./ — In a city full of brilliant engineers and developers thanks to the automotive and agricultural industries, Detroit has a lot to offer when providing professional influence on emerging industries, including cannabis. Established in 2017, Royal Oak based company, Growater Controls acknowledges advanced automated controls that are a necessity in flower, vegetable or cannabis growing facilities to help owners manage energy and labor costs, along with conserving water and fertilizers.  While engaging with growers utilizing advanced automated control systems, it became obvious that up front system integration and documented routine preventive maintenance procedures play an essential role in the success of a grow operation.
Control installations often fall short due to the collaboration between vendors, engineers, electricians, plumbers and owners. This is true with simple single zone controllers and advanced control systems such as Climate Control Systems, Argus, HortiMaX and Priva. Once operating, failures arise due to lack of proper system integration efforts, system training and routine system maintenance. Growater Controls is changing that with their team of engineers from their parent company, Coritech Services, who have been providing turn-key solutions for automation and power controls for over 20 years. With Coritech’s extensive experience working with companies such as Ford, GM, DTE Energy, and even the US Military, they offer the growing industry the skilled engineering and support that is needed to control all sizes of a growing operation.

While environmental controls, irrigation management, and water purification systems are commonly used in a grow, the power to run these systems along with all the other equipment required to fully operate is usually overlooked. Backup power is dire especially in states like Michigan where it was reported that the state alone had over 40 weather related power outages according to Eatons Blackout Tracker Report in 2015. Growater is providing power management solutions that are designed by their full-time staff of mechanical and electrical engineers to make sure that your grow is always online and operating if a power outage strikes.

Whether you’re in the beginning stages of a grow, adding on a system to a current grow, or just need help supporting your current grow, Growater Controls can provide a solution that delivers the most out of an automated system setup for maximum production. Start growing in control and learn more about the benefits of automation by visiting www.GrowaterControls.com or call (248) 850-1190.

SOURCE Growater Controls

10
Jan

Australia to Allow Exportation of Cannabis Products

VANCOUVER, British ColumbiaJan. 5, 2018 /MYM Nutraceuticals Inc. (CSE: MYM) (CSE: MYM.CN) (OTC: MYMMF) (“MYM“) is excited to announce that Australia will expunge the export ban on cannabis products in February 2018 and allow the worldwide exportation of cannabis-based treatments such as oils, patches, sprays, lozenges and tablets. The Australian Federal Government has big ambitions for Australia to become the largest producer of medicinal cannabis products in the world.

Australia’s Health Minister Greg Hunt stated, “We would like to be, potentially, the world’s number one medicinal cannabis supplier.  One of the conditions of any license for export is that medicinal cannabis be made available to Australian patients first. The sector is fully supportive of that. Australian patients come first. There are now no real government barriers at all to accessing medicinal cannabis.”

This is fantastic news for MYM since it has an Australian joint venture company, Solaris Nutraceuticals, that is currently in the assessment phase of the licensing process to build a 1.2 million square-foot greenhouse facility set to be the largest cannabis production facility in Australia.  MYM expects that exportation of cannabis products from Australia will be big business and could even outstrip domestic sales.

About MYM Nutraceuticals Inc.

logo

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in CanadaGermany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

About Solaris Nutraceuticals Inc.

Image result for Solaris Nutraceuticals

Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. It has submitted an application and plans with Australia’s Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia.  Solaris’s corporate mission is to deliver environmentally friendly, sun-grown medicinal-grade cannabis and to develop medicines and treatments for pain management and other medical conditions. The company’s focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information, visit www.solarisnutraceuticals.com.

SOURCE MYM Nutraceuticals Inc.

10
Jan

Introducing Toast Gold™ — The Champagne Of Cannabis

ASPEN, Colo.Jan. 10, 2018 / — Toast™, the only lifestyle Cannabis brand that provides a sophisticated, consumer-controlled Cannabis experience by offering the first professionally-manufactured filtered pre-roll, called a Slice™, is pleased to announce the introduction of Toast Gold™, the world’s first and only Cannabis product designed to mirror the strength and effect of one glass of Champagne.

Each Slice of Toast Gold contains a proprietary, all-natural, tobacco-free 100% Cannabis blend composed of curated strains that are low in THC (euphoria) and high in CBD (active calm), resulting in a light, effervescent effect for the consumer while still allowing them to be present, in control and active, just as if they sipped one glass of Champagne in a social setting.

A single Slice of Toast Gold is designed to be consumed in its entirety by one person, just like a glass of Champagne, whereas a pack of Slices™ is meant to be shared with friends or family, just like a bottle of Champagne.

A single Slice of Toast Gold, The Champagne of Cannabis, is designed to be consumed in its entirety by one person, just like a glass of Champagne, whereas a pack of Slices is meant to be shared with friends or family, just like a bottle of Champagne.

Toast currently offers Slices in Toast Gold and Toast Original™ blends, with each product containing different levels of THC potency, similar to the alcohol by volume (ABV) measurement system found in wine and spirits. Toast Gold is a lighter blend of Toast that provides an effect similar to one glass of Champagne with 4:1 CBD:THC. Toast Original is a stronger blend of Toast with 2:1 CBD:THC, which parallels the strength of one bar-measured cocktail.

Because Toast is professionally manufactured and tested against the highest quality assurance standards, every Slice of Toast will always contain a measured dose of CBD and THC, which allows for a predictability of potency and intake that can be regulated, just like alcohol, ultimately enabling the consumer to control their experience unlike any other Cannabis product on the market.

Toast Gold is available in 5-packs (MSRP $45) and 2-packs (MSRP $20) at select authorized dispensaries in Colorado. For a complete list of where to purchase Toast Gold or Toast Original or for more information about Toast and/or its future availabilities in other states, please visit https://wetoast.com/. Must be 21 years of age or older.

About Toast™
Toast™ is the only lifestyle Cannabis brand that provides a sophisticated, consumer-controlled experience by offering the first professionally manufactured filtered pre-roll, called a Slice™. Each Slice of Toast contains a proprietary, all-natural, tobacco-free 100% Cannabis blend composed of curated strains that are low in THC (euphoria) and high in CBD (active calm). A single Slice is designed to be consumed in its entirety by one person, whereas a pack of Slices™ is meant to be shared with friends and family. Toast currently offers Slices in Toast Gold™ and Toast Original™, where one slice of Toast Gold is like one glass of Champagne, and one slice of Toast Original is like one bar-measured cocktail. Because Toast is professionally manufactured and tested against the highest quality assurance standards, every Slice allows for a predictability of potency and intake that can be regulated, ultimately enabling the consumer to control their experience unlike any other Cannabis product on the market. For more information about Toast, please visit https://wetoast.com/. General email inquiries can be directed to info@wetoast.com. Must be 21 years of age or older.

SOURCE Toast Holdings, Inc.

10
Jan

Cannabis Market Sales on the Rise According to Data

NEW YORKJanuary 10, 2018/ — According to a research report by New Frontier Data, medical cannabis sales are forecast to grow to$5.3 billion in 2017, accounting for 67% of total cannabis sales. Medical sales in currently legal states are estimated to grow to$13.2 billion by 2025, at which point medical sales will account for 55% of all sales. In comparison, adult-use sales in 2017 are forecast to reach$2.6 billion, rising to$10.9 billion by 2025. A major development in the cannabis industry is California’s new recreational cannabis laws, which went into effect on January 1st, 2018. New Frontier also indicates that legal cannabis sales in California alone are projected to reach $2.8 billion in 2017 and $6.6 billion by 2025, with a compound annual growth rate of 12% over the next eight years. Cannabis Wheat on Income Corp. (OTC: CBWTF), Lexaria Bioscience Corp. (OTC: LXRP), AXIM Biotechnologies, Inc. (OTC: AXIM), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Canopy Growth Corporation (OTC: TWMJF)

State budget deficits may be resolved as cannabis revenue could raise a significant amount and provide states with increased capacity in their finances. New Frontier Data CEO Giadha Aguirre De Carcer said, “During this tough economy states are looking for any way to close their budget shortfalls and it appears that cannabis may hold an answer for them. New Frontier Data looked at the potential revenues that could be generated from state cannabis taxes and found that in this year alone, states could raise nearly$750 million and triple that number by 2020. These revenues will have a meaningful impact on state programs and provide governors with much needed breathing room in their budgets.”

Cannabis Wheat on Income Corp. (OTC: CBWTF) is also listed on the TSX Venture Exchange under the ticker symbol ‘CBW’. Earlier this week the company announced that, “as a result of strong investor demand, it has increased the size of its previously announced private placement offering of convertible debenture units to up to $100 million (the “Offering”). Terms of the Offering are more particularly described in the Company’s news release issued on December 22, 2017.

The net proceeds received by the Company will be used to fund working capital and general corporate purposes, including but not limited to, financing of the Company’s streaming partners pursuant to certain streaming agreements and general and administrative expenses. Subject to the satisfaction of customary closing conditions, including receipt of the approval of the TSX Venture Exchange, the Offering is expected to close on or about January 12, 2018.

MMCAP International Inc. SPC (the “Lead Subscriber”) and the Company have executed an amended binding term sheet with respect to the Offering, whereby the Lead Subscriber has agreed to subscribe for up to $68,000,000 million aggregate principal amount of convertible debenture units under the Offering. The Lead Subscriber is considered to be a related party of the Company for the purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) and Policy 5.9 – Protection of Minority Security Holders in Special Transactions of the TSX Venture Exchange, making the Offering a “related party transaction”. Pursuant to MI 61-101, the Company has today filed a material change report providing disclosure in relation to the “related party transaction” on SEDAR under the Company’s issuer profile athttp://www.sedar.com. The Company did not file the material change report describing the increase to the size of the Offering more than 21 days prior to the expected closing date of the Offering as the definitive documentation for the Offering and the participation therein by the Lead Subscriber and any other “related party” of the Company were settled less than 21 days prior to the expected closing date of the Offering, and the Company wishes to close the Offering on an expedited basis for sound business reasons.”

Lexaria Bioscience Corp. (OTCQX: LXRP) has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. On December 15, 2017, the company announced a new topical skin cream research and development (“R&D”) program; R&D into nicotine edibles; and updates existing R&D programs. Lexaria has formulated topical cream products as an extension of its DehydraTECH™ technology, for the delivery of cannabinoids into and through the skin which may prove to have emollient benefits desired by the topical products sector. Multiple Lexaria formulations are scheduled to be laboratory tested for human skin absorption and penetration characteristics during January through March 2018. Testing will be completed at a third-party lab utilizing human skin tissue and the latest in vitro evaluative techniques to measure cannabidiol penetration in the skin. Lexaria expects to optimize formulation and manufacturing processes to develop superior-performing product designs that will potentially be available to licensees during 2018.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. On November 21, 2017, the company announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. Study results indicate that CanChew+® was well tolerated by the IBS patients and no significant adverse side effects were observed by any participants of the trial. All patients who participated in the study experienced decrease in their levels of pain score. On top of the overall reduction, the trend curve suggests 50% higher pain reduction when patients were on CanChew+® compared to the active placebo, which suggests that CBD content did lend to a decrease in pain score. As overall pain scores were reduced, the study also validates AXIM’s use of its proprietary chewing gum delivery system.

Corbus Pharmaceuticals Holdings, Inc(NASDAQ:CRBP) is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. On December 22, 2017, the company announced the initiation of a Phase 2 clinical study of anabasum for the treatment of systemic lupus erythematosus (“SLE”). SLE is an uncommon autoimmune disease associated with significant morbidity, reduction in quality of life and a 2.4-fold increase in standard mortality rate. The disease affects primarily women of child-bearing age, with increased prevalence and morbidity among African Americans and other minority populations. Anabasum is a synthetic, oral, small-molecule, selective cannabinoid receptor type 2 (CB2) agonist that preferentially binds to CB2 expressed on activated immune cells and fibroblasts.

Canopy Growth Corporation (OTC: TWMJF) is a world-leading diversified cannabis company, offering distinct brands and curated cannabis varieties in dried, oil and capsule forms. On November 28, 2017, the company announced it has entered into a distribution agreement with Winnipeg-based Delta 9 Cannabis Inc., an existing Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). Delta 9 will offer their well-established cannabis products through Canopy Growth’s curated Craft Grow line via Tweed Main Street’s online store, alongside other high-quality cannabis varieties grown by a diverse set of producers. Delta 9 was founded in 2012, and quickly became the fourth fully licensed producer and distributor of medical cannabis in Canada. Currently operating an 80,000 sq. ft. production facility in East Winnipeg, Delta 9 is focused on growing small batch, hand trimmed medical cannabis strains in its innovative, self-designed Grow Pod systems.

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided onhttp://www.FinancialBuzz.com(the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For cannabis wheat on income corp. financial news dissemination and PR services, FinancialBuzz.com has been compensated four thousand dollars for financial news dissemination and pr services by winning media. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:http://www.financialbuzz.com.

SOURCE FinancialBuzz.com

12
Sep

14th Annual Cannabis World Congress & Business Exposition Opens in Los Angeles

Cannabis Means Business #CWCBEXPO

What: 

4th Annual Cannabis World Congress & Business Exposition in Los Angeles (CWCBExpo) www.cwcbexpo.com

When:  ‪

September 13, 2017 – Add-On Workshops (education only)

September 14-15, 2017 – Keynote, Exhibits, and Conference Program

Where:  

Los Angeles Convention Center, West Hall B

‪1201 South Figueroa Street‪

Los Angeles, CA 90015

The Cannabis World Congress & Business Expositions (CWCBExpo) in Los Angeles is the leading event on the West Coast for the legalized adult use, medical marijuana, and industrial hemp industries. For three days and all under one roof, CWCBExpo LA features education, information, and products for navigating and prospering in this high growth industry.

CWCBExpo Los Angeles, September 13-15, 2017.

Taking place in California, which was the first state to legalize medical marijuana, and is now poised to be one of the biggest global cannabis markets with the legalization of recreational adult use, CWCBExpo LA is the go-to source for entrepreneurs, investors, established business owners, and the medical community to learn what is happening now and in the future.

Highlights of CWCBExpo in LA include:

  • Keynote Address by Rev. Al Sharpton (‪Sept. 14, 11:50 am) on decriminalization and civil rights.
  • Educational classes covering everything from “Scaling Up – From Small to Large Grows”; “Regulations and Licensing in the City of Los Angeles“; “Breaking the Grass Ceiling”; “From Grow to Glow: Hemp & Healthy Skin”; “Investing in Cannabis: Emerging Trends in a Fast Evolving Market”; “Issues of Social Marijuana Use and the Future of Public Consumption”; “Infusing Edibles for the Future”; and much more with over 75 content-rich sessions being presented.
  • Top Cannabis experts and trailblazers sharing their knowledge and insight including Avis Bulbulyan, SIVA; Dr. Philip Blair (retired US Army colonel); Giadha de Carcer, Frontier Financials; Amy Diiullo, Willie’s Reserve; Damon Elliot, NOMAD; Wanda James, Simply Pure; and Rick Scarpello, Incredibles; to name a few.
  • New products and services for the cannabis industry including full service cannabis business development firm SIVA; hemp-derived CBD manufacturer Elixinol; cannabis and fertilizer manufacturer Advanced Nutrients; high quality organic medicinal hemp from Folium Biosciences; pure natural CBD products from Isodiol; engineered cultivation systems, greenhouses, grow lights, vaping systems, extractors, security systems, operating software and technologies, lab testing, packaging, dry trimmers, and more.
  • Five Add-On Workshops– that provide in-depth information and targeted training: Open a Cannabis Business presented by Clover Leaf University; Responsible Vendor: Best Practices for a Dispensary and Interpening: The Art of the Cannabis Sommelier presented by Trichome Institute; Hemp MBA in a Day presented by Canna Pro Series; How to Buy Equity in a Cannabis Business: What to Look for, What to Avoid, presented by New Frontier Data
  • Season 3 auditions including local Los Angeles contestants for The Marijuana Show, the “shark tank” of cannabis shows, and chance for $20 million “high finance” fund.

Billions can be made in the cannabis industry in every sector of business from manufacturing and logistics to legal and financial services.  Savvy entrepreneurs, service providers, dispensary owners, medical professionals, cultivators, retailers, and investors from the West Coast, across the country, and around the world are registering for CWCBExpo LA to find out how to succeed in the cannabis industry.  Go to www.cwcbexpo.com for more information.

SOURCE Cannabis World Congress & Business Expositions

X